821 related articles for article (PubMed ID: 20028613)
1. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
Thompson Coon J; Hoyle M; Green C; Liu Z; Welch K; Moxham T; Stein K
Health Technol Assess; 2010 Jan; 14(2):1-184, iii-iv. PubMed ID: 20028613
[TBL] [Abstract][Full Text] [Related]
2. Sunitinib, sorafenib, temsirolimus or bevacizumab in the treatment of metastatic renal cell carcinoma: a review of health economic evaluations.
Norum J; Nieder C; Kondo M
J Chemother; 2010 Apr; 22(2):75-82. PubMed ID: 20435564
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies.
Hutson TE; Figlin RA; Kuhn JG; Motzer RJ
Oncologist; 2008 Oct; 13(10):1084-96. PubMed ID: 18838439
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab plus interferon-α versus sunitinib for first-line treatment of renal cell carcinoma in Italy: a cost-minimization analysis.
Ravasio R; Ortega C; Sabbatini R; Porta C
Clin Drug Investig; 2011; 31(7):507-17. PubMed ID: 21627339
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness.
Thompson Coon JS; Liu Z; Hoyle M; Rogers G; Green C; Moxham T; Welch K; Stein K
Br J Cancer; 2009 Jul; 101(2):238-43. PubMed ID: 19568242
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma.
Benedict A; Figlin RA; Sandström P; Harmenberg U; Ullén A; Charbonneau C; Sandin R; Remák E; Hariharan S; Négrier S
BJU Int; 2011 Sep; 108(5):665-72. PubMed ID: 21265994
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain.
Calvo Aller E; Maroto P; Kreif N; González Larriba JL; López-Brea M; Castellano D; Martí B; Díaz Cerezo S
Clin Transl Oncol; 2011 Dec; 13(12):869-77. PubMed ID: 22126730
[TBL] [Abstract][Full Text] [Related]
8. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Miller K; Bergmann L; Albers P; Gschwend J; Jäger E; Keilholz U
Aktuelle Urol; 2010 May; 41(3):193-6. PubMed ID: 20486036
[TBL] [Abstract][Full Text] [Related]
9. Update on systemic therapies of metastatic renal cell carcinoma.
Herrmann E; Bierer S; Wülfing C
World J Urol; 2010 Jun; 28(3):303-9. PubMed ID: 20180125
[TBL] [Abstract][Full Text] [Related]
10. [Economic evaluation of targeted biologic therapy in metastatic renal cell carcinoma].
Ondrácková B; Demlová R; Komínek J
Klin Onkol; 2010; 23(6):439-45. PubMed ID: 21351422
[TBL] [Abstract][Full Text] [Related]
11. Beyond traditional outcomes: improving quality of life in patients with renal cell carcinoma.
Cella D
Oncologist; 2011; 16 Suppl 2(Suppl 2):23-31. PubMed ID: 21346037
[TBL] [Abstract][Full Text] [Related]
12. Metastatic renal cell cancer treatments: an indirect comparison meta-analysis.
Mills EJ; Rachlis B; O'Regan C; Thabane L; Perri D
BMC Cancer; 2009 Jan; 9():34. PubMed ID: 19173737
[TBL] [Abstract][Full Text] [Related]
13. Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies.
Ravaud A
Oncologist; 2011; 16 Suppl 2(Suppl 2):32-44. PubMed ID: 21346038
[TBL] [Abstract][Full Text] [Related]
14. Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.
Muriel C; Esteban E; Corral N; Fonseca PJ; Luque M; Berros JP; Fernández Y; Blay P; Fra J; Villanueva N; Sanmamed M; Pardo P; Izquierdo M; Vieitez JM; Estrada E; Lacave ÁJ
Clin Transl Oncol; 2010 Aug; 12(8):562-7. PubMed ID: 20709657
[TBL] [Abstract][Full Text] [Related]
15. First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
Takyar S; Diaz J; Sehgal M; Sapunar F; Pandha H
Anticancer Drugs; 2016 Jun; 27(5):383-97. PubMed ID: 26886011
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma.
Hoyle M; Green C; Thompson-Coon J; Liu Z; Welch K; Moxham T; Stein K
Value Health; 2010; 13(1):55-60. PubMed ID: 19804431
[TBL] [Abstract][Full Text] [Related]
17. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
Di Lorenzo G; Buonerba C; Federico P; Rescigno P; Milella M; Ortega C; Aieta M; D'Aniello C; Longo N; Felici A; Ruggeri EM; Palmieri G; Imbimbo C; Aglietta M; De Placido S; Mirone V
Eur Urol; 2010 Dec; 58(6):906-11. PubMed ID: 20884115
[TBL] [Abstract][Full Text] [Related]
18. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
Fernández-Pello S; Hofmann F; Tahbaz R; Marconi L; Lam TB; Albiges L; Bensalah K; Canfield SE; Dabestani S; Giles RH; Hora M; Kuczyk MA; Merseburger AS; Powles T; Staehler M; Volpe A; Ljungberg B; Bex A
Eur Urol; 2017 Mar; 71(3):426-436. PubMed ID: 27939075
[TBL] [Abstract][Full Text] [Related]
19. Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy.
Schmidinger M; Zielinski CC
Cancer Treat Rev; 2009 May; 35(3):289-96. PubMed ID: 19232474
[TBL] [Abstract][Full Text] [Related]
20. [Value of targeted therapies for renal cell cancer].
Merseburger AS; Kuczyk MA
Urologe A; 2008 Oct; 47(10):1303-10. PubMed ID: 18587556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
